Send to

Choose Destination
See comment in PubMed Commons below
Am J Clin Oncol. 2010 Dec;33(6):619-23. doi: 10.1097/COC.0b013e3181c4c6e1.

A surveillance, epidemiology, and end results registry analysis of prostate cancer modality time trends by age.

Author information

  • 1Department of Radiation Oncology, Emory University, Atlanta, GA, USA.



To use the Surveillance, Epidemiology, and End Results (SEER) registry to analyze age-specific time trends in the use of radiotherapy (RT) (external beam radiotherapy [EBRT], brachytherapy [brachy], and combination therapy [combo]) as first-line treatment for prostate cancer.


A total of 820,649 prostate cancer patients in the SEER public-use registry (1973-2004) with diagnosis year, treatment, and age information available were identified. Modality use time-trend curves were plotted for patients 45 to 85+ years of age, grouped in 5-year intervals. A nonparametric (Spearman) test was used to assess the correlation between diagnosis year and (a) percentage use of RT and (b) relative percentage use of EBRT, brachy, and combo therapy.


Over the study period from 1973 to 2004, RT use increased in patients ≥65 years of age, but has remained stable in patients <65 years of age. All age groups experienced a similar relative rise in the use of brachy and combo therapy, with brachy use surpassing combo use in approximately year 2000.


Trends in treatment choice for early prostate cancer generally reflect treatment advances, but do not appear to be uniform among all age groups. The SEER database is a valuable asset for analyzing these trends and can be used to investigate age-specific treatment patterns.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Support Center